Robert W. Baird Cuts IQVIA (NYSE:IQV) Price Target to $212.00

IQVIA (NYSE:IQV) had its price target reduced by Robert W. Baird from $213.00 to $212.00 in a research report report published on Wednesday morning,Benzinga reports. They currently have a neutral rating on the medical research company’s stock.

Other equities research analysts have also recently issued research reports about the stock. Leerink Partners reaffirmed an “outperform” rating and issued a $248.00 price target (down previously from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. TD Cowen reduced their target price on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, November 1st. The Goldman Sachs Group dropped their price target on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. William Blair reiterated an “outperform” rating on shares of IQVIA in a research note on Wednesday. Finally, Royal Bank of Canada restated an “outperform” rating and set a $270.00 target price on shares of IQVIA in a research report on Wednesday, December 4th. Four research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $256.19.

IQVIA Stock Performance

NYSE IQV opened at $199.06 on Wednesday. The company has a market capitalization of $36.13 billion, a PE ratio of 26.12, a price-to-earnings-growth ratio of 2.07 and a beta of 1.49. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. IQVIA has a 52-week low of $187.62 and a 52-week high of $261.73. The company has a 50-day simple moving average of $212.24 and a 200 day simple moving average of $224.23.

Institutional Trading of IQVIA

Several institutional investors and hedge funds have recently made changes to their positions in IQV. First Foundation Advisors raised its position in IQVIA by 3.8% during the second quarter. First Foundation Advisors now owns 1,161 shares of the medical research company’s stock valued at $245,000 after purchasing an additional 43 shares in the last quarter. Invera Wealth Advisors LLC lifted its position in IQVIA by 0.3% in the 2nd quarter. Invera Wealth Advisors LLC now owns 14,506 shares of the medical research company’s stock worth $3,183,000 after buying an additional 46 shares during the last quarter. Private Trust Co. NA grew its position in IQVIA by 10.7% during the third quarter. Private Trust Co. NA now owns 485 shares of the medical research company’s stock valued at $115,000 after acquiring an additional 47 shares during the last quarter. Oregon Public Employees Retirement Fund raised its stake in shares of IQVIA by 0.3% during the second quarter. Oregon Public Employees Retirement Fund now owns 15,668 shares of the medical research company’s stock worth $3,313,000 after acquiring an additional 48 shares in the last quarter. Finally, Continuum Advisory LLC lifted its holdings in shares of IQVIA by 3.3% in the 2nd quarter. Continuum Advisory LLC now owns 1,538 shares of the medical research company’s stock worth $325,000 after acquiring an additional 49 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.